natgillin/translations-raw huggingface dataset:
• Active pathological bleeding such as peptic ulcer or intracranial haemorrhage.
• aktivnog patološkog krvarenja, poput peptičkog ulkusa ili intrakranijalnog krvarenja.
A metabolic acidosis also arises due to the presence of salicylates.
Također nastaje metabolička acidoza, zbog prisutnosti salicilata.
This was associated with a reduction of the mean inhibition of platelet aggregation by 15% and 11%, respectively.
To je bilo povezano sa smanjenjem srednje vrijednosti inhibicije agregacije trombocita od 15% i 11%.
• if you have a condition known as glucose-6-phosphate dehydrogenase (G6PD) deficiency because of the risk of a particular form of anaemia (low number of red blood cells).
• ako imate nedostatak glukoza-6-fosfat dehidrogenaze (G6PD), zbog rizika od određene vrste anemije (nizak broj crvenih krvnih stanica).
Posology Adults and elderly
Odrasli i starije osobe
Reproduction toxicity data show that ASA is teratogenic in several laboratory animals.
Podaci o reproduktivnoj toksičnosti pokazuju da ja ASK teratogena u nekoliko laboratorijskih životinja.
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolesnici s rijetkim nasljednim poremećajima nepodnošenja galaktoze, potpunim nedostatkom laktaze ili malapsorpcijom glukoze i galaktoze ne bi smjeli uzimati ovaj lijek.
• In patients with ST segment elevation acute myocardial infarction: Therapy should be started as early as possible after symptoms start and continued for at least four weeks.
• U bolesnika s akutnim infarktom miokarda s elevacijom ST-segmenta: liječenje treba započeti što je ranije moguće nakon pojave simptoma te nastaviti tijekom najmanje četiri tjedna.
When poor metabolisers received the 600 mg/150 mg regimen, active metabolite exposure was greater than with the 300 mg/75 mg regimen.
Kad su spori metabolizatori primili režim od 600 mg/150 mg, izloženost aktivnom metabolitu bila je veća nego kod režima od 300 mg/75 mg.
A number of other clinical studies have been conducted with clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic (PK) interactions.
Provedeno je još nekoliko drugih kliničkih studija s klopidogrelom i nekim drugim istodobno primjenjivanim lijekovima kako bi se ispitala mogućnost farmakodinamičkih i farmakokinetičkih (PK) interakcija.
With severe intoxication, serious disturbances of the acid-base equilibrium occur.
Kod teške intoksikacije pojavljuje se ozbiljni poremećaj acidobazne ravnoteže.
(See section 4.5.)
(vidjeti dio 4.4)
Clinical studies indicate that doses up to 100 mg/day for restricted obstetrical use, which require specialised monitoring, appear safe.
Klinička ispitivanja upućuju na to da se primjena doze do 100 mg dnevno, u ograničenoj opstetricijskoj uporabi, koja zahtijeva posebno praćenje, čini sigurna.
• if you are allergic to clopidogrel, acetylsalicylic acid (ASA) or any of the other ingredients of this medicine (listed in section 6).
• ako ste alergični na klopidogrel, acetilsalicilatnu kiselinu (ASK) ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.),
Single-dose studies have shown that the oral toxicity of ASA is low.
Ispitivanja s jednokratnom dozom pokazala su da je oralna toksičnost ASK niska.
During non-clinical studies in rat and baboon, the most frequently observed effects were liver changes.
Tijekom nekliničkih ispitivanja na štakorima i babunima, najčešće su uočene promjene na jetri.
Depression of the nervous system can lead to coma, cardiovascular collapse and respiratory arrest.
Depresija živčanog sustava može dovesti do kome, kardiovaskularnog kolapsa i respiratornog zastoja.
Alkalising of the urine (250 mmol sodium bicarbonate for 3 hours) while monitoring the urine pH is indicated.
Potrebno je alkalizirati urin (250 mmol natrijeva bikarbonata tijekom 3 sata) uz praćenje pH urina.
The population included 27.8% women, 58.4% patients ≥60 years (26% ≥70 years) and 54.5% patients who received fibrinolytics.
Populacija bolesnika uključivala je 27,8% žena, 58,4% bolesnika ≥ 60 godina (26% ≥ 70 godina) i 54,5% bolesnika koji su primali fibrinolitike.
A patient with poor metaboliser status will possess two loss-of function alleles as defined above.
Bolesnici sa statusom sporih metabolizatora imaju 2 nefunkcionalna alela kako je definirano gore.
If you forget to take Clopidogrel/Acetylsalicylic acid Mylan If you forget to take a dose of Clopidogrel/Acetylsalicylic acid Mylan, but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time.
Ako ste zaboravili uzeti lijek Klopidogrel/acetilsalicilatna kiselina Mylan Ako zaboravite uzeti dozu lijeka Klopidogrel/acetilsalicilatna kiselina Mylan, ali se toga sjetite u roku od 12 sati od uobičajenog vremena uzimanja, odmah uzmite tabletu, a sljedeću tabletu uzmite u uobičajeno vrijeme.
• Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
• preosjetljivosti na djelatne tvari ili neku od pomoćnih tvari navedenih u dijelu 6.1,
At high ASA doses, the elimination of salicylic acid follows zero-order kinetics (i.e., the rate of elimination is constant in relation to plasma concentration), with an apparent half-life of 6 hours or higher.
Pri visokim dozama ASK, eliminacija salicilatne kiseline slijedi kinetiku nultog reda (tj. brzina eliminacije je konstantna u odnosu na koncentraciju u plazmi), s prividnim poluvijekom života od 6 sati i više.
There is insufficient clinical experience regarding the use of doses above 100 mg/day up to 500 mg/day.
Nema dovoljno kliničkog iskustva s primjenom doza iznad 100 - 500 mg dnevno.
Less pronounced reductions of metabolite exposure has been observed with pantoprazole or lansoprazole.
Manje izraženo smanjenje izloženosti metabolitu opaženo je kod pantoprazola ili lanzoprazola.
Treat other signs of intoxication symptomatically.
Ostali znakovi intoksikacije liječe se simptomatski.
• fever, signs of infection or extreme tiredness.
• vrućicu, znakove infekcije ili teškog umora.
The results obtained in populations with different characteristics (e.g. unstable angina or non-Q-wave MI, low to high risk levels, diabetes, need for revascularisation, age, gender, etc.) were consistent with the results of the primary analysis.
Rezultati koji su dobiveni u različitim populacijama ispitanika (primjerice nestabilna angina ili non-Q infarkt miokarda, niski ili visoki stupanj rizika, šećerna bolest, potreba za revaskularizacijom, dob, spol itd.) bili su sukladni rezultatima primarne analize.
In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy.
U studiji CURE, 823 bolesnika (6,6%) istodobno je primalo antagoniste receptora GPIIb/IIIa.
Poly (vinyl alcohol) (partially hydrolysed) Titanium dioxide (E171)
Poli(vinilni alkohol) (djelomično hidroliziran) Titanijev dioksid (E171)
Clopidogrel:
Klopidogrel:
Low doses (up to 100 mg/day):
Niske doze (do 100 mg dnevno):
Platelets are very small structures in the blood which clump together during blood clotting.
Trombociti su vrlo mala krvna tjelešca tzv. krvne pločice koje se nakupljaju tijekom zgrušavanja krvi.
For the treatment of this condition your doctor may have placed a stent in the blocked or narrowed artery to restore effective blood flow.
Za liječenje tog stanja liječnik Vam je možda ugradio stent (cjevčicu koja krvnu žilu drži protočnom) u začepljenu ili suženu arteriju da bi ponovno uspostavio normalan protok krvi.
Minor GI symptoms, such as dyspepsia, are common and can occur anytime during therapy.
Manji gastrointestinalni simptomi, poput dispepsije, su česti i mogu se pojaviti u bilo koje vrijeme tijekom liječenja.
• if you drink alcohol, because of the increased risk of bleeding or gastrointestinal injury.
• ako pijete alkohol, zbog povećanog rizika od krvarenja ili oštećenja probavnog sustava
If patients must temporarily stop antiplatelet therapy, Clopidogrel/Acetylsalicylic acid Mylan should be discontinued 7 days prior to surgery.
Ako bolesnik mora privremeno prekinuti antitrombocitnu terapiju, lijek Klopidogrel/acetilsalicilatna kiselina Mylan treba prestati uzimati 7 dana prije kirurškog zahvata.
Other alleles associated with absent or reduced metabolism are less frequent and include CYP2C19*4, *5, *6, *7, and *8.
Ostali aleli povezani s nedostatkom metabolizma ili smanjenim metabolizmom su manje zastupljeni i uključuju CYP2C19*4, *5, *6, *7 i *8.
The co-primary endpoints were death from any cause and the first occurrence of re-infarction, stroke or death.
Koprimarni ishod bila je smrt zbog bilo kojeg uzroka i prvi ponovljeni infarkt, moždani udar ili smrt.
ASA is poorly bound to plasma proteins and its apparent volume of distribution is low (10 l).
ASK se slabo veže na proteine plazme te je njezin prividni volumen distribucije nizak (10 l).
If you take more Clopidogrel/Acetylsalicylic acid Mylan than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding.
Ako uzmete više lijeka Klopidogrel/acetilsalicilatna kiselina Mylan nego što ste trebali Odmah morate kontaktirati liječnika ili najbliži odjel hitne medicinske pomoći zbog povećanog rizika od krvarenja.
Glycoprotein IIb/IIIa inhibitors
Inhibitori glikoproteina IIb/IIIa
The plasma concentrations of the active metabolite was 20% reduced (loading dose) and 14% reduced (maintenance dose) during concomitant treatment with pantoprazole 80 mg once daily.
Koncentracija aktivnog metabolita u plazmi bila je smanjena za 20% (udarna doza) i 14% (doza održavanja) tijekom istodobnog liječenja pantoprazolom u dozi od 80 mg jednom dnevno.
Reye's Syndrome is a very rare disease which can be fatal.
Reyeov sindrom je vrlo rijetka bolest koja može imati smrtni ishod.
• if you are allergic to other products called non-steroidal anti-inflammatory products usually used to treat painful and/or inflammatory conditions of muscles or joints.
• ako ste alergični na druge lijekove koji se zovu nesteroidni protuupalni lijekovi i koji se obično koriste za liječenje bolnih i/ili upalnih stanja mišića ili zglobova,
The safety and efficacy of clopidogrel/acetylsalicylic acid in children and adolescents under 18 years old have not been established.
Sigurnost i djelotvornost klopidogrel/acetilsalicilatne kiseline u djece i adolescenata do 18 godina starosti još nije ustanovljena.
Pharmacotherapeutic group: group: ATC code: Antithrombotic agents, platelet aggregation inhibitors excl. Heparin, ATC Code: B01AC30.
Farmakoterapijska skupina: skupina: ATK oznaka: antitrombotici, inhibitori agregacije trombocita izuzev heparina, ATK oznaka: B01AC30.
The benefit of the combination of clopidogrel with ASA beyond four weeks has not been studied in this setting (see section 5.1).
Korist kombinacije klopidogrela s ASK u trajanju dužem od 4 tjedna nije ispitivana u ovim okolnostima (vidjeti dio 5.1).
Recent transient ischaemic attack or stroke
Nedavna tranzitorna ishemijska ataka (TIA) ili moždani udar
For minor cuts and injuries e.g., cutting yourself shaving, this is usually of no concern.
Za male posjekotine ili ozljede, primjerice, porezotine nastale tijekom brijanja, obično se ne trebate zabrinjavati.
Following therapeutic doses, approximately 10% is found excreted in the urine as salicylic acid, 75% as salicyluric acid, 10% phenolic- and 5% acylglucuronides of salicylic acid.
Nakon terapijskih doza, otprilike 10% se izluči urinom u obliku salicilatne kiseline, 75% u obliku salicilurične kiseline, 10% u obliku fenolnih i 5% u obliku acil glukuronida salicilatne kiseline.
CYP2C8 substrate medicinal products: Clopidogrel has been shown to increase repaglinide exposure in healthy volunteers.
Lijekovi koji su supstrati CYP2C8: Pokazalo se da klopidogrel povećava izloženost repaglinidu u zdravih dobrovoljaca.
Clopidogrel and the main circulating (inactive) metabolite bind reversibly in vitro to human plasma proteins (98% and 94% respectively).
Klopidogrel i glavni cirkulirajući (neaktivni) metabolit se in vitro reverzibilno vežu za proteine u ljudskoj plazmi (98% odnosno 94%).
Other concomitant therapy with clopidogrel
Ostala istodobna terapija s klopidogrelom
Its metabolite, salicylic acid, is highly bound to plasma proteins, but its binding is concentration dependent (nonlinear).
Njezin metabolit, salicilatna kiselina, u velikoj se mjeri veže na proteine plazme, ali vezanje ovisi o koncentraciji (nelinearno).
Other interactions with ASA
Ostale interakcije s ASK
Repeat-dose toxicity studies have shown that levels up to 200 mg/kg/day are well tolerated in rats; dogs appear to be more sensitive, probably due to the high sensitivity of canines to the ulcerogenic effects of NSAIDs.
Ispitivanja toksičnosti ponovljenih doza pokazala su da su koncentracije do 200 mg/kg dnevno štakori dobro podnosili, dok su psi bili osjetljiviji, vjerojatno zbog visoke osjetljivosti pasa na ulcerogene učinke NSAIL-a.
Doses of 100-500 mg/day:
Doze od 100 - 500 mg dnevno:
The recommended dose is one tablet of Clopidogrel/Acetylsalicylic acid Mylan per day to be taken orally with a glass of water, with or without food.
Preporučena doza je jedna tableta lijeka Klopidogrel/acetilsalicilatna kiselina Mylan dnevno koja se uzima kroz usta, s čašom vode, s hranom ili bez nje.
Other medicines and Clopidogrel/Acetylsalicylic acid Mylan Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Drugi lijekovi i Klopidogrel/acetilsalicilatna kiselina Mylan Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
Patients should inform physicians and dentists that they are taking Clopidogrel/Acetylsalicylic acid Mylan before any surgery is scheduled and before any new medicinal product is taken.
Bolesnici trebaju obavijestiti liječnika ili stomatologa o uzimanju lijeka Klopidogrel/acetilsalicilatna kiselina Mylan prije planiranja bilo kakvog kirurškog zahvata i prije početka uzimanja bilo kojeg novog lijeka.
Clinical trial data support use up to 12 months, and the maximum benefit was seen at 3 months (see section 5.1).
Rezultati kliničkih ispitivanja podupiru trajanje liječenja do najviše 12 mjeseci, a najveći učinak zabilježen je nakon 3 mjeseca liječenja (vidjeti dio 5.1).
Salicylic acid is widely distributed to all tissues and fluids in the body, including the central nervous system, breast milk, and foetal tissues.
Salicilatna kiselina dobro je raspodijeljena po svim tkivima i tekućinama u tijelu uključujući središnji živčani sustav, majčino mlijeko i fetalno tkivo.
For patients who did not undergo angiography, the primary endpoint was death or recurrent myocardial infarction by Day 8 or by hospital discharge.
Za bolesnike kojima nije učinjena angiografija primarni ishod bila je smrt ili rekurentni infarkt miokarda do osmog dana ili do otpusta iz bolnice.
The following symptoms can also arise: hyperthermia and perspiration, leading to dehydration, restlessness, convulsions, hallucinations and hypoglycaemia.
Mogu se pojaviti i sljedeći simptomi: hipertermija i znojenje koji vode do dehidracije, nemir, konvulzije, halucinacije i hipoglikemija.
When given to lactating rats, clopidogrel caused a slight delay in the development of the offspring.
Kad se davao ženkama štakora u vrijeme laktacije, klopidogrel je izazivao neznatno usporeni razvoj mladunčadi.
These results indicate that clopidogrel can be administered with pantoprazole.
Ovi rezultati upućuju na to da se klopidogrel može primjenjivati istodobno s pantoprazolom.
The European Medicines Agency has waived the obligation to submit the results of studies with the reference medical product containing clopidogrel /acetylsalicyclic acid in all subsets of the paediatric population in the treatment of coronary atherosclerosis (see section 4.2 for information on paediatric use).
Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka koji sadrže klopidogrel/acetilsalicilatnu kiselinu u svim podskupinama pedijatrijske populacije u liječenju koronarne ateroskleroze (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
Repeated doses of clopidogrel 75 mg per day produced substantial inhibition of ADP-induced platelet aggregation from the first day; this increased progressively and reached steady state between Day 3 and Day 7.
Ponovljene doze klopidogrela od 75 mg dnevno uzrokuju snažnu inhibiciju ADP-om posredovane agregacije trombocita od prvog dana; to se progresivno pojačava i doseže stanje dinamičke ravnoteže između dana 3 i dana 7.
Therefore, the recommendations below for doses of 500 mg/day and above apply also for this dose range.
Stoga se ispod navedene preporuke za dnevne doze od 500 mg i više odnose i na ovaj raspon doza.
Clopidogrel/Acetylsalicylic acid Mylan should not be used during the first two trimesters of pregnancy unless the clinical condition of the woman requires treatment with clopidogrel/ASA.
Klopidogrel/acetilsalicilatna kiselina Mylan ne smije se koristiti tijekom prva dva tromjesečja trudnoće, osim ako kliničko stanje bolesnice zahtijeva liječenje klopidogrelom/ASK.
As no clinical data on exposure to clopidogrel during pregnancy are available, it is preferable not to use clopidogrel during pregnancy as a precautionary measure.
S obzirom na to da nema dostupnih kliničkih podataka o izloženosti klopidogrelu tijekom trudnoće, preporučljivo je, kao mjera opreza, ne koristiti klopidogrel za vrijeme trudnoće.
The binding is non-saturable in vitro over a wide concentration range.
Vezanje in vitro nije zasićeno u širokom rasponu koncentracije.
There was no observed effect on the rate of rehospitalisation for unstable angina.
Nije primijećen učinak na stopu ponovljene hospitalizacije zbog nestabilne angine.
Within each system organ class, adverse reactions are presented in order of decreasing seriousness.
Unutar svake klasifikacije organskog sustava nuspojave su prikazane u padajućem nizu prema ozbiljnosti.
There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers or antacids interfere with antiplatelet activity of clopidogrel.
Nema dokaza da drugi lijekovi koji smanjuju lučenje želučane kiseline, poput H2 - blokatora ili antacida, utječu na antitrombocitni učinak klopidogrela.
Other interactions with clopidogrel and ASA
Ostale interakcije s klopidogrelom i ASK
• acetazolamide, a medicine used to treat glaucoma (increased ocular pressure) or epilepsy or to increase urine flow,
• acetazolamid, lijek koji se koristi za liječenje glaukoma (povišenog očnog tlaka) ili epilepsije ili za povećanje protoka urina,
In patients who remained on therapy within five days of bypass graft surgery, the event rate was 9.6% for clopidogrel plus ASA, and 6.3% for placebo plus ASA.
U bolesnika koji su terapiju nastavili primati i unutar 5 dana do ugrađivanja premosnice, stopa krvarenja bila je 9,6% za klopidogrel plus ASK, odnosno 6,3% za placebo plus ASK.
Omeprazole 80 mg once daily administered either at the same time as clopidogrel or with 12 hours between the administrations of the two drugs decreased the exposure of the active metabolite by 45% (loading dose) and 40% (maintenance dose).
Omeprazol primijenjen u dozi od 80 mg dnevno, istodobno s klopidogrelom ili s razmakom od 12 sati između primjene dvaju lijekova, smanjio je izloženost aktivnom metabolitu za 45% (udarna doza) i 40% (doza održavanja).
Metamizole
Metamizol
This effect lasts for the life of the platelet.
Ovaj učinak traje do kraja životnog vijeka trombocita.
There was no evidence of carcinogenic effect when clopidogrel was administered for 78 weeks to mice and 104 weeks to rats when given at doses up to 77 mg/kg per day (representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day).
Nije bilo dokaza o karcinogenim učincima kad se klopidogrel davao miševima 78 tjedana i štakorima 104 tjedna u dozama do 77 mg/kg dnevno (što predstavlja najmanje 25 puta veću izloženost od one primijećene u ljudi kod primijenjene kliničke doze od 75 mg/dan).
In CHARISMA and one cohort study (Simon), an increased event rate was observed only in poor metabolisers when compared to extensive metabolisers.
U studiji CHARISMA i jednoj kohortnoj studiji (Simon), povećana stopa događaja bila je zapažena samo u sporih metabolizatora, u usporedbi s brzim metabolizatorima.
In a clinical study conducted in healthy subjects, clopidogrel did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.
U kliničkom ispitivanju sa zdravim ispitanicima, primjena klopidogrela nije zahtijevala promjenu doze heparina, niti je mijenjala učinak heparina na koagulaciju.
• This medicinal product must be administered under close medical supervision in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to risk of haemolysis (see section 4.8).
• Ovaj se lijek mora primjenjivati pod strogim liječničkim nadzorom u bolesnika s nedostatkom glukoza-6-fosfat dehidrogenaze (G6PD) zbog rizika od hemolize (vidjeti dio 4.8).
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 2 ‘Warnings and precautions').
Ako ste ipak zabrinuti zbog krvarenja, odmah obavijestite svog liječnika (vidjeti dio 2. „Upozorenja i mjere opreza”).
In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%.
U studiji CAPRIE, u bolesnika koji su se liječili klopidogrelom ili ASK, ukupna incidencija krvarenja iznosila je 9,3%.
A pharmacodynamic interaction between Clopidogrel/Acetylsalicylic acid Mylan and heparin is possible, leading to increased risk of bleeding.
Farmakodinamička interakcija između lijeka Klopidogrel/acetilsalicilatna kiselina Mylan i heparina je moguća i može povećati rizik od krvarenja.
Published frequencies for the poor CYP2C19 metaboliser genotypes are approximately 2% for Caucasians, 4% for Blacks and 14% for Chinese.
Učestalost genotipova sporih CYP2C19 metabolizatora prema objavljenim podacima iznosi otprilike 2% za bijelce, 4% za crnce i 14% za Kineze.
Specific pharmacokinetic studies performed with radiolabelled clopidogrel have shown that the parent compound or its metabolites are excreted in the milk.
Specifične farmakokinetičke studije provedene s radioaktivno označenim klopidogrelom pokazale su da se ishodišni spoj klopidogrel ili njegovi metaboliti izlučuju u mlijeko.
As with other oral P2Y12 inhibitors, co-administration of opioid agonists has the potential to delay and reduce the absorption of clopidogrel presumably because of slowed gastric emptying.
Kao i kod drugih oralnih P2Y12 inhibitora, istodobna primjena agonista opioida može potencijalno odgoditi i smanjiti apsorpciju klopidogrela, pretpostavlja se zbog usporenog želučanog pražnjenja.
A total of 99.7% of patients received fibrinolytics (fibrin-specific: 68.7%, non-fibrin specific: 31.1%), 89.5% heparin, 78.7% beta blockers, 54.7% ACE inhibitors and 63% statins.
Fibrinolitike je primalo 99,7% bolesnika (fibrin-specifični: 68,7%, fibrin-nespecifični: 31,1%), 89,5% heparin, 78,7% beta blokatore, 54,7% ACE inhibitore i 63% statine.
The CYP2C19*2 and CYP2C19*3 alleles account for the majority of reduced function alleles in Caucasian (85%) and Asian (99%) poor metabolisers.
CYP2C19*2 i CYP2C19*3 aleli čine većinu alela sa smanjenom funkcijom u sporih metabolizatora u bijelaca (85%) i Azijata (99%).
In vitro and in vivo, clopidogrel is metabolised according to two main metabolic pathways: one mediated by esterases and leading to hydrolysis into its inactive carboxylic acid derivative (85% of circulating metabolites), and one mediated by multiple cytochromes P450.
In vitro i in vivo, klopidogrel se metabolizira kroz dva glavna metabolička puta: jedan posredovan esterazama, koji dovodi do hidrolize u neaktivni derivat karboksilne kiseline (koji čini 85% cirkulirajućih metabolita) i drugi posredovan s više enzima citokroma P450.
C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing.
C radioaktivno označenog klopidogrela u ljudi, otprilike 50% doze se izlučuje u urinu te otprilike 46% u fecesu u razdoblju od 120 sati nakon doziranja.